• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

IRBM

Monday, June 03, 2024
CP
Multiple Therapeutics
RBM stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate. With a history of contributing to four approved drugs, and it’s own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields.
IRBM
Company Website: https://www.irbm.com/
Lead Product in Development: We have two lead programs, one is a potential best in class brain-penetrant SHP2 inhibitor (pre-clinical phase), and the other is a first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in “Ph-like” B-ALL (discovery phase)
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Company HQ City

Pomezia

Company HQ State

Lazio

Company HQ Country

Italy

CEO/Top Company Official

Ilaria Di Lorenzo

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS